Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions

20260 citationsJournal Article

Authors

A. Hussain · University of Maryland, Baltimore

Abstract

Clinical practice is converging on early comprehensive genomic testing and prioritization of PARPi-based therapy for HRR-altered, especially BRCA1/2 -mutated, prostate cancer. Key research priorities include functional biomarkers beyond gene panels, rational combinations to prevent/overcome resistance, and optimized sequencing across disease states.

Topics & Keywords

Prostate Cancer Treatment and Research PARP inhibition in cancer therapy Prostate Cancer Diagnosis and Treatment

Publication Details

Published in: Current Opinion in Oncology

Volume 38, Issue 3, pp. 249-260

DOI: 10.1097/cco.0000000000001230

Field-Weighted Citation Impact: 0.00

Command Palette

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions

Authors

Abstract

Topics & Keywords

Publication Details